Intramedullary Nail Fixation with Autologous Bone Marrow Transplantation in an Incomplete Atypical Femoral Fracture Patient: Use of Bone Marrow Extracted from the Hollow Reamer

The present report describes an incomplete atypical femoral fracture (AFF) patient who underwent simultaneous autogenous bone transplantation to the resected fracture region during intramedullary nail fixation. A 73-year-old female with a history of multiple myeloma had been undergoing treatment with intravenous drip injections of Zoledronic Acid. She was introduced to our department due to the left lateral thigh pain, with no trauma incidence. An anteroposterior radiograph showed a transverse thin fracture line with localized periosteal and endosteal thickening, which is compatible with subtrochanteric incomplete AFF. A biochemical investigation revealed the existence of severely suppressed bone turnover. She underwent intramedullary nail fixation for fear of a complete fracture. After the fixation, the cortical bone at the fracture region was excised as a wedge-shaped block, and bone marrow extracted from the hollow reamer was simultaneously transplanted to the resected fracture region. Histological examination showed few bone formation features at the fracture line in the excised lateral cortical bone. At 7 months after surgery, radiographs demonstrated complete bone repair, and no clinical problems were observed two years postoperatively. To the best of our knowledge, this is the first report in which autogenous bone marrow transplantation, noninvasive to the iliac crest, was performed in an incomplete AFF patient. We believe that this low invasive procedure can be a useful technique for AFF treatment.

[1]  A. Lovy,et al.  IM Nail Fixation of Atypical Femur Fractures with Bone Marrow Aspirate Concentrate Leads to Faster Union: A Case Control Study. , 2017, Journal of orthopaedic trauma.

[2]  J. Schilcher,et al.  Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series , 2017, Osteoporosis International.

[3]  S. Ponnazhagan,et al.  Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade. , 2016, Bone.

[4]  H. Kato,et al.  Factors that characterize bone health with aging in healthy postmenopausal women , 2015, Journal of Bone and Mineral Metabolism.

[5]  J. Schilcher,et al.  Histology of 8 atypical femoral fractures , 2014, Acta orthopaedica.

[6]  T. Howe,et al.  Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. , 2014, The bone & joint journal.

[7]  S. Elliman,et al.  From isolation to implantation: a concise review of mesenchymal stem cell therapy in bone fracture repair , 2014, Stem Cell Research & Therapy.

[8]  P. Syson,et al.  Construct Failure in an Atypical Femoral Fracture treated with Intramedullary Nailing: A Case Report , 2014, Malaysian orthopaedic journal.

[9]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  T. Howe,et al.  Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. , 2012, AJR. American journal of roentgenology.

[11]  J. Babb,et al.  Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. , 2012, AJR. American journal of roentgenology.

[12]  T. Howe,et al.  Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture? , 2010, Journal of orthopaedic trauma.

[13]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[14]  T. Howe,et al.  Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. , 2007, The Journal of bone and joint surgery. British volume.

[15]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.